Acute Coronary Syndrome News and Research

RSS

World Heart Federation, Daiichi Sankyo and Lilly Partner to improve cardiovascular health

The World Heart Federation, Daiichi Sankyo Company, and Eli Lilly announced today that they have partnered to improve cardiovascular health internationally. The organizations made the announcement at the 58th Annual Scientific Session of the American College of Cardiology in Orlando, Florida.

31 Mar 2009

Study answers question of timing in use of eptifibatide

An international study to resolve a decade of debate over the best timing for administering an anti-clotting drug for certain heart patients has come up with an answer: It doesn't matter.

30 Mar 2009

Study offers closer look at Takotsubo cardiomyopathy

"Broken heart syndrome" is still a mystery to many in the medical community, but new data from researchers at The Miriam Hospital may shed some light on the clinical characteristics and outcomes of this relatively rare, life-threatening condition.

29 Mar 2009

Schering-Plough's investigational oral thrombin receptor antagonist meets primary endpoint in a newly published study

Results of a Schering-Plough Corporation Phase II trial of SCH 530348, a novel oral thrombin receptor antagonist (TRA), were published today in The Lancet and demonstrated that the investigational antiplatelet compound met its primary endpoints of safety and tolerability.

12 Mar 2009

New drug derived from magnolia trees proves safe, tolerable in preventing blood clots

A new drug derived from magnolia trees appears to be able to uncouple two important functions of thrombin in blood clot formation and may offer a way to better control the potentially dangerous complications of bleeding and clot formation during procedures to open blocked coronary arteries, say researchers at the Duke Clinical Research Institute (DCRI).

12 Mar 2009

Certain combined medications after heart attack may increase risk of death

Following an acute coronary syndrome such as a heart attack or unstable angina, patients who receive a medication to reduce the risk of gastrointestinal bleeding that may be associated with the use of the antiplatelet drug clopidogrel and aspirin have an increased risk of subsequent hospitalization for acute coronary syndrome or death, according to a study in the March 4 issue of JAMA, the Journal of the American Medical Association.

3 Mar 2009

FDA to review prasugrel for acute coronary syndromes

Daiichi Sankyo Company, Limited and Eli Lilly and Company has confirmed that the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) will review prasugrel during an advisory committee hearing on February 3, 2009.

1 Jan 2009

Portola Pharmaceuticals starts phase 2 trial of P2Y12 ADP receptor antagonist in non-urgent percutaneous coronary intervention

Portola Pharmaceuticals has announced that it has initiated patient enrollment in INNOVATE-PCI, a large Phase II clinical trial of PRT060128, the Company's novel P2Y12 ADP receptor antagonist, in patients undergoing non-urgent percutaneous coronary intervention (PCI).

10 Dec 2008

Idiopathic pulmonary fibrosis linked to heart attacks

Patients with idiopathic pulmonary fibrosis (IPF) are three times as likely to experience severe coronary events - including heart attacks - than people without the disease, according to a recent study that analyzed the risk of cardiovascular disease in nearly 1,000 patients with IPF and more than 3,500 matched controls.

5 Dec 2008

Mechanisms of cardiovascular disease and cancer give clues to new therapies

Cardiovascular conditions leading to heart attacks and strokes are treated quite separately from common cancers of the prostate, breast or lung, but now turn out to involve some of the same critical mechanisms at the molecular level.

21 Nov 2008

Timing is everything for some heart attack patients

There is strong evidence that getting to the hospital quickly during a heart attack is critical, since early treatment saves both lives and heart muscle. And if the responsible coronary artery is completely blocked, it should be opened as soon as possible.

11 Nov 2008

Rivaroxaban shows promise in patients with acute coronary syndrome

Researchers reported on a study of a new oral anti-clotting agent - rivaroxaban - designed to identify doses that would be safe to test in subsequent Phase III efficacy and safety trials. The results of ATLAS ACS-TIMI 46 were presented as a late-breaking clinical trial at the American Heart Association's Scientific Sessions 2008.

11 Nov 2008

VIA Pharmaceuticals announces results of phase 2 trials of VIA-2291 in cardiovascular disease

VIA Pharmaceuticals, Inc. has announced the results of two Phase 2 studies of its lead drug, VIA-2291.

10 Nov 2008

FDA approves Ranexa for the treatment of chronic angina

CV Therapeutics, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved a new, first line indication for Ranexa(R) (ranolazine extended-release tablets) for the treatment of chronic angina.

7 Nov 2008

Post-traumatic stress disorder symptoms linked to increased risk of death after heart events

Individuals who receive implantable cardiac defibrillators after a sudden heart event appear more likely to die within five years if they experience symptoms of post-traumatic stress disorder, regardless of the severity of their disease, according to a report in the November issue of Archives of General Psychiatry.

4 Nov 2008

Vulnerable plaque may be easier to detect through optical coherence tomography

Research results indicate that optical coherence tomography (OCT), a newly evolving imaging method, may be the best tool available to detect vulnerable plaque in coronary arteries. The findings will be presented at the 20th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF).

12 Oct 2008

Safety of antithrombotic treatment in acute coronary syndromes

The management of acute coronary syndromes (with or without ST segment elevation) requires the use of anticoagulants, antiplatelet agents (aspirin, clopidogrel and/or glycoprotein (GP) IIb/IIIa inhibitors), beta-blockers, thrombolytics in some cases, and revascularization / reperfusion.

2 Sep 2008

Factor Xa inhibitor Apixaban and antiplatelet therapy after acute coronary syndrome

Data from a phase II study of an investigational drug designed to block formation of blood clots show potential for added protection against a second heart attack or stroke among patients who are already taking state-of-the-art prevention therapy.

2 Sep 2008

New biomarkers in acute cardiac care

In conjunction with clinical assessment and the ECG, simple and rapid blood tests have become the standard for the detection of myocardial infarction. Starting in the year 2000, recommendations by the European Society of Cardiology and other major cardiology societies worldwide have begun to state uniformly that a rise in cardiac troponins - sensitive and specific markers for dying cells in the heart - is a prerequisite for the clinical diagnosis of myocardial infarction.

1 Sep 2008

Issues on cholesterol: diet, statins and genetics

Genetic lipoprotein disorders are frequently seen in patients with premature coronary artery disease (CAD). An example of strong genetic predisposition is the disorder: familial hypercholesterolemia, where a single gene defect (the low density lipoprotein receptor) contributes to most of the familial expression of CAD.

1 Sep 2008